Human IL17A Monoclonal Antibody

Größe

£355.00

SKU:: YR0100
Zusätzliche Namen:: CTLA-8|CTLA8|IL-17|IL-17A|IL17|ILA17
Anwendung:: ELISA, FuncS, Neutralisation
Molekulargewicht:: 150 kDa
Reinheit:: >95%
Lagerbedingungen:: 2-8[o]C Avoid freeze/thaw cycles., -70[o]C Avoid freeze/thaw cycles.
Hersteller:: Abclonal
Immunogen:: Human IL17A
Formulierung:: Purified from cell culture supernatant in an animal-free facility
Uniprot:: Q16552
Synonyme:: CTLA-8;CTLA8;cytotoxic T-lymphocyte-associated antigen 8;cytotoxic T-lymphocyte-associated protein 8;IL-17;IL-17A;IL17;ILA17;interleukin 17 (cytotoxic T-lymphocyte-associated serine esterase 8);interleukin-17;interleukin-17A
Weitere Details:: What is secukinumab biosimilar research grade? Research grade secukinumab biosimilar uses the same protein sequences as the therapeutic antibody secukinumab. Secukinumab, the humanized anti-IL17A monoclonal antibody, inhibits interleukin 17A, which is a member of the cytokine family, and produced mainly by inflammatory T helper 17 cells. IL17A is upregulated in serum of people with psoriasis and in the synovial fluid of people with psoriatic arthritis, and promotes inflammation when it binds to the interleukin-17 receptor which is expressed in various types of cells, including keratinocytes in skin.